DR

Dylan Reid

Partner @ Zetta

New York, New York

Education

Work Experience

  • Managing Director

    2025

  • Partner

    2018 - 2025

2024

  • Investor / Advisor

    2024

    Building multi-modal models of toxicology to close the "translational gap" in AI drug development.

  • Investor / Observer

    2021

    Using Protein Language Models and Massively Multiplex Screening to Design Impossible Antibodies.

2022

  • Investor / Observer

    2022

    Using Foundation Models and Spatial Biology to Discover Targeted Immunotherapies.

  • Investor / Director

    2019

    Using LLMs to Design Better, Faster, More Efficient Clinical Trials.

  • Investor / Advisor

    2023

    Building a better therapy experience with licensed clinicians and clinical-grade LLMs

2022

  • Investor / Director

    2022

    Using AI and Combinatorial Chemistry to Design Non-Viral Delivery Vehicles for mRNA

  • Investor

    2022

    Software for closed-loop science. Small personal investor, big believer.

  • Investor

    2018

    Semi-autonomous forklifts. Pre-seed investor (first check).

  • Investor

    2017

    AI-first industrial inspection. Pre-seed investor.